Historical record - last NADAC publication: 10/21/2020
Product Information
TRIMETHOBENZAMIDE 300 MG CAP is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $1.2941 per EA under NDC 43386066024. Its NADAC has been published 412 times since Nov 28, 2013.
Strength
300 mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
43386066024
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
10/21/2020
Active Ingredients
TRIMETHOBENZAMIDE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA076546On Market Since
1/17/2011
Pharmacological Classes
Price Statistics
The NADAC for TRIMETHOBENZAMIDE 300 MG CAP has been published 412 times since Nov 28, 2013, and over the history we have for it it has risen 2.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2941 per EA |
|---|---|
| All-time high | $1.4016 (Oct 12, 2016) |
| All-time low | $1.0201 (Aug 22, 2018) |
| Median price | $1.2297 |
| Average price | $1.2279 |
| Largest weekly change | +24.5% (Dec 19, 2018) |
| Weeks tracked | 412 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TRIMETHOBENZAMIDE 300 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for TRIMETHOBENZAMIDE 300 MG CAP, manufactured by Lupin Pharmaceuticals Inc., is $1.2941 per EA (NDC 43386066024), effective Oct 13, 2021.
How has the price of TRIMETHOBENZAMIDE 300 MG CAP changed over time?
Over the history we have for it, the NADAC for TRIMETHOBENZAMIDE 300 MG CAP has risen 2.3%. It has been tracked across 412 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRIMETHOBENZAMIDE 300 MG CAP?
Since Nov 28, 2013, the NADAC for TRIMETHOBENZAMIDE 300 MG CAP has ranged from a low of $1.0201 (Aug 22, 2018) to a high of $1.4016 (Oct 12, 2016), with a median of $1.2297 per EA.
Are there cheaper alternatives to TRIMETHOBENZAMIDE 300 MG CAP?
2 NADAC-published products share the same active ingredient, strength, and dosage form as TRIMETHOBENZAMIDE 300 MG CAP, but none are currently priced below it.
Who manufactures TRIMETHOBENZAMIDE 300 MG CAP?
TRIMETHOBENZAMIDE 300 MG CAP (NDC 43386066024) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification